Literature DB >> 28465256

A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection.

M Rätsep1, S Kõljalg2, E Sepp2, I Smidt2, K Truusalu2, E Songisepp3, J Stsepetova2, P Naaber2, R H Mikelsaar2, M Mikelsaar4.   

Abstract

Clostridium difficile infection (CDI) is one of the most prevalent healthcare associated infections in hospitals and nursing homes. Different approaches are used for prevention of CDI. Absence of intestinal lactobacilli and bifidobacteria has been associated with C. difficile colonization in hospitalized patients. Our aim was to test a) the susceptibility of C. difficile strains of different origin and the intestinal probiotic Lactobacillus plantarum Inducia (DSM 21379) to various antimicrobial preparations incl. metronidazole, vancomycin; b) the susceptibility of C. difficile strains to antagonistic effects of the probiotic L. plantarum Inducia, prebiotic xylitol (Xyl) and their combination as a synbiotic (Syn) product; c) the suppression of germination of C. difficile spores in vitro and in vivo in animal model of C. difficile infection with Inducia, Xyl and Syn treatment. The VPI strain 10463 (ATCC 43255), epidemic strain (M 13042) and clinical isolates (n = 12) of C. difficile from Norway and Estonia were susceptible and contrarily L. plantarum Inducia resistant to vancomycin, metronidazole and ciprofloxacin. The intact cells of Inducia, natural and neutralized cell free supernatant inhibited in vitro the growth of tested C. difficile reference strain VPI and Estonian and Norwegian clinical isolates of C. difficile after co-cultivation. This effect against C. difficile sustained in liquid media under ampicillin (0.75 μg/ml) and Xyl (5%) application. Further, incubation of Inducia in the media with 5% Xyl fully stopped germination of spores of C. difficile VPI strain after 48 h. In infection model the 48 hamsters were administered ampicillin (30 mg/kg) and 10-30 spores of C. difficile VPI strain. They also received five days before and after the challenge a pretreatment with a synbiotic (single daily dose of L. plantarum Inducia 1 ml of 1010 CFU/ml and 20% xylitol in 1 ml by orogastric gavage). The survival rate of hamsters was increased to 78% compared to 13% (p = 0.003) survival rate of hamsters who received no treatment. When administered Xyl the survival rate of hamsters reached 56% vs.13% (p = 0.06). In both Syn (6/9, p = 0.003) and Xyl (3/9, p = 0.042) groups the number of animals not colonized with C. difficile significantly increased. In conclusion, the combination of xylitol with L. plantarum Inducia suppresses the germination of spores and outgrowth into vegetative toxin producing cells of C. difficile and reduces the colonization of gut with the pathogen. Putative therapeutical approach includes usage of the synbiotic during antimicrobial therapy for prevention of CDI and its potential to reduce recurrences of CDI.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotic susceptibility; Clostridium difficile; Lactobacillus plantarum inducia; Prevention; Spores; Xylitol

Mesh:

Substances:

Year:  2017        PMID: 28465256     DOI: 10.1016/j.anaerobe.2017.03.019

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  14 in total

Review 1.  Probiotics for prevention of Clostridium difficile infection.

Authors:  John P Mills; Krishna Rao; Vincent B Young
Journal:  Curr Opin Gastroenterol       Date:  2018-01       Impact factor: 3.287

2.  Lactiplantibacillus plantarum E51 protects against Clostridioides difficile-induced damages on Caco-2 intestinal barrier functions.

Authors:  Huey-Sheng Jeng; Tsong-Rong Yan
Journal:  Arch Microbiol       Date:  2022-05-03       Impact factor: 2.667

Review 3.  Advances in the diagnosis and treatment of Clostridium difficile infections.

Authors:  Zhong Peng; Lifen Ling; Charles W Stratton; Chunhui Li; Christopher R Polage; Bin Wu; Yi-Wei Tang
Journal:  Emerg Microbes Infect       Date:  2018-02-07       Impact factor: 7.163

Review 4.  Xylitol's Health Benefits beyond Dental Health: A Comprehensive Review.

Authors:  Krista Salli; Markus J Lehtinen; Kirsti Tiihonen; Arthur C Ouwehand
Journal:  Nutrients       Date:  2019-08-06       Impact factor: 5.717

5.  Antibacterial Activity of Bifidobacterium breve Against Clostridioides difficile.

Authors:  Jingpeng Yang; Hong Yang
Journal:  Front Cell Infect Microbiol       Date:  2019-08-07       Impact factor: 5.293

6.  Multi-omics investigation of Clostridioides difficile-colonized patients reveals pathogen and commensal correlates of C. difficile pathogenesis.

Authors:  Skye Rs Fishbein; John I Robinson; Tiffany Hink; Kimberly A Reske; Erin P Newcomer; Carey-Ann D Burnham; Jeffrey P Henderson; Erik R Dubberke; Gautam Dantas
Journal:  Elife       Date:  2022-01-27       Impact factor: 8.140

Review 7.  Gut Dysbiosis and Clostridioides difficile Infection in Neonates and Adults.

Authors:  Iulia-Magdalena Vasilescu; Mariana-Carmen Chifiriuc; Gratiela Gradisteanu Pircalabioru; Roxana Filip; Alexandra Bolocan; Veronica Lazăr; Lia-Mara Diţu; Coralia Bleotu
Journal:  Front Microbiol       Date:  2022-01-20       Impact factor: 5.640

8.  Protective Effects of Bifidobacterial Strains Against Toxigenic Clostridium difficile.

Authors:  Yanxia Wei; Fan Yang; Qiong Wu; Jing Gao; Wenli Liu; Chang Liu; Xiaokui Guo; Sharmila Suwal; Yanbo Kou; Bo Zhang; Yugang Wang; Kuiyang Zheng; Renxian Tang
Journal:  Front Microbiol       Date:  2018-05-08       Impact factor: 5.640

9.  Protective Effect of Pediococcus pentosaceus LI05 Against Clostridium difficile Infection in a Mouse Model.

Authors:  Qiaomai Xu; Silan Gu; Yunbo Chen; Jiazheng Quan; Longxian Lv; Dazhi Chen; Beiwen Zheng; Lichen Xu; Lanjuan Li
Journal:  Front Microbiol       Date:  2018-10-09       Impact factor: 5.640

10.  Frontiers in antibiotic alternatives for Clostridioides difficile infection.

Authors:  Matthew Phanchana; Phurt Harnvoravongchai; Supapit Wongkuna; Tanaporn Phetruen; Wichuda Phothichaisri; Supakan Panturat; Methinee Pipatthana; Sitthivut Charoensutthivarakul; Surang Chankhamhaengdecha; Tavan Janvilisri
Journal:  World J Gastroenterol       Date:  2021-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.